145 related articles for article (PubMed ID: 26583684)
1. Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.
Kuijer A; van Bommel AC; Drukker CA; van der Heiden-van der Loo M; Smorenburg CH; Westenend PJ; Linn SC; Rutgers EJ; Elias SG; van Dalen T
Genet Med; 2016 Jul; 18(7):720-6. PubMed ID: 26583684
[TBL] [Abstract][Full Text] [Related]
2. The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer.
van Steenhoven JEC; Kuijer A; Schreuder K; Elias SG; van Diest PJ; van der Wall E; Siesling S; van Dalen T
Ann Surg Oncol; 2019 Oct; 26(11):3495-3501. PubMed ID: 31209664
[TBL] [Abstract][Full Text] [Related]
3. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S
Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015
[TBL] [Abstract][Full Text] [Related]
4. Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
Kuijer A; Drukker CA; Elias SG; Smorenburg CH; Th Rutgers EJ; Siesling S; van Dalen T
Int J Cancer; 2016 Aug; 139(4):769-75. PubMed ID: 27062369
[TBL] [Abstract][Full Text] [Related]
5. Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study.
Kuijer A; Straver M; den Dekker B; van Bommel ACM; Elias SG; Smorenburg CH; Wesseling J; Linn SC; Rutgers EJT; Siesling S; van Dalen T
J Clin Oncol; 2017 Aug; 35(24):2814-2819. PubMed ID: 28813638
[TBL] [Abstract][Full Text] [Related]
6. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
[TBL] [Abstract][Full Text] [Related]
7. The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-stage breast cancer in the Netherlands.
Kuijer A; Verloop J; Visser O; Sonke G; Jager A; van Gils CH; van Dalen T; Elias SG
Ann Oncol; 2017 Aug; 28(8):1970-1978. PubMed ID: 28459994
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
Knauer M; Mook S; Rutgers EJ; Bender RA; Hauptmann M; van de Vijver MJ; Koornstra RH; Bueno-de-Mesquita JM; Linn SC; van 't Veer LJ
Breast Cancer Res Treat; 2010 Apr; 120(3):655-61. PubMed ID: 20204499
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant systemic therapy in early breast cancer: impact of guideline changes and clinicopathological factors associated with nonadherence at a nation-wide level.
Verschoor AM; Kuijer A; Verloop J; Van Gils CH; Sonke GS; Jager A; van Dalen T; Elias SG
Breast Cancer Res Treat; 2016 Sep; 159(2):357-65. PubMed ID: 27514397
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
Aalders KC; Kuijer A; Straver ME; Slaets L; Litiere S; Viale G; Van't Veer LJ; Glas AM; Delorenzi M; van Dalen T; Tryfonidis K; Piccart MJ; Cardoso F; Rutgers EJ;
Eur J Cancer; 2017 Jul; 79():98-105. PubMed ID: 28477490
[TBL] [Abstract][Full Text] [Related]
11. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
[TBL] [Abstract][Full Text] [Related]
12. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
[TBL] [Abstract][Full Text] [Related]
13. MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Soliman H; Shah V; Srkalovic G; Mahtani R; Levine E; Mavromatis B; Srinivasiah J; Kassar M; Gabordi R; Qamar R; Untch S; Kling HM; Treece T; Audeh W
BMC Cancer; 2020 Jan; 20(1):81. PubMed ID: 32005181
[TBL] [Abstract][Full Text] [Related]
14. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated with the Use of Gene Expression Profiles in Estrogen Receptor-Positive Early-Stage Breast Cancer Patients: A Nationwide Study.
Kuijer A; Schreuder K; Elias SG; Smorenburg CH; Rutgers EJ; Siesling S; van Dalen T
Public Health Genomics; 2016; 19(5):276-81. PubMed ID: 27508402
[TBL] [Abstract][Full Text] [Related]
16. The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients.
van Dooijeweert C; Baas IO; Deckers IAG; Siesling S; van Diest PJ; van der Wall E
Breast Cancer Res Treat; 2021 Jun; 187(2):577-586. PubMed ID: 33517555
[TBL] [Abstract][Full Text] [Related]
17. Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
van Steenhoven JEC; den Dekker BM; Kuijer A; van Diest PJ; Nieboer P; Zuetenhorst JM; Imholz ALT; Siesling S; van Dalen T
Breast Cancer Res Treat; 2020 Jul; 182(1):107-115. PubMed ID: 32430679
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling to predict the risk of locoregional recurrence in breast cancer: a pooled analysis.
Drukker CA; Elias SG; Nijenhuis MV; Wesseling J; Bartelink H; Elkhuizen P; Fowble B; Whitworth PW; Patel RR; de Snoo FA; van 't Veer LJ; Beitsch PD; Rutgers EJ
Breast Cancer Res Treat; 2014 Dec; 148(3):599-613. PubMed ID: 25414025
[TBL] [Abstract][Full Text] [Related]
19. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
20. A high-risk 70-gene signature is not associated with the detection of tumor cell dissemination to the bone marrow.
Walter VP; Taran FA; Wallwiener M; Walter C; Grischke EM; Wallwiener D; Brucker SY; Hartkopf AD
Breast Cancer Res Treat; 2018 Jun; 169(2):305-309. PubMed ID: 29374853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
